CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the first patient has been ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions, today ...

Cellular-stress-focused biotech Ribon Therapeutics has hired former Novartis VP and Flagship Pioneering Senior Partner Prakash Raman, Ph.D., as its new CEO. Raman most recently was senior partner at ...

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced the appointment of Paul Brannelly as Chief Financial Officer. Mr.

Ribon Therapeutics has raised $65 million to advance a pipeline led by a PARP7 inhibitor deeper into the clinic. The financing positions Ribon to build on work to target stress support pathways in ...